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Abstract
Background: Currently, there is no standard salvage regimen after the failure of cisplatin-based chemotherapy for
advanced urothelial carcinoma. The combination of epidermal growth factor receptor inhibitor with fluorouracil,
leucovorin, and irinotecan was originally designed for the treatment of metastatic colorectal cancer. Until now,
there have been no reports using this combination therapy in treating advanced upper tract urothelial carcinoma. To the
best of our knowledge, this is the first report showing this possible treatment regimen for advanced upper tract urothelial
carcinoma.
Case presentation: We report the case of a 90-year-old Chinese woman who was diagnosed with metastatic colorectal
cancer and urothelial carcinoma of the bladder, ureter, and renal pelvis. The upper tract urothelial carcinoma was well
controlled by the chemotherapy regimen for metastatic colorectal cancer. Considering her age, we used only
laser ablation for the treatment of her urothelial carcinoma in combination with intravesical mitomycin C chemotherapy.
Follow-up cystoscopy and ureterorenoscopy showed an unexpected regression of the upper tract urothelial tumor.
Contrast-enhanced computed tomography also demonstrated the same results.
Conclusions: This novel regimen for the treatment of upper tract urothelial carcinoma may merit further investigation
or evaluation in clinical trials.
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Background
Upper tract urothelial carcinomas (UTUCs) are tumors de-
rived from the urothelium along the pyelocaliceal cavities
and ureters, and they account for only 5–10 % of urinary
tract carcinomas [1]. Radical nephroureterectomy (RNU)
with bladder cuff excision, using either open or laparo-
scopic methods, is the gold standard treatment for ad-
equate local tumor control and better long-term survival
[2]. Despite optimal surgical treatment, patient outcomes
are still not satisfactory. Until now, no definitive evidence
has existed regarding the use of perioperative chemother-
apy in the management of UTUC. The current practice
guideline is almost entirely derived from research related to
muscle-invasive bladder cancer [3]. Though cisplatin-based
chemotherapy is the current first-line therapy regimen, its
efficacy remains poorly defined [3]. Furthermore, there is
no standard salvage regimen after the failure of cisplatin-
based chemotherapy. We recently treated a double cancer
case with metastatic colorectal cancer and urothelial carcin-
oma of the bladder, ureter, and renal pelvis. The UTUC
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was well controlled by the chemotherapy regimen for meta-
static colorectal cancer.
Case presentation
A 90-year-old Chinese woman with a complaint of bloody
stool was admitted to our department of general surgery to
undergo surgery for colorectal cancer. She also mentioned
intermittent painless gross hematuria with blood clots for
months. She has been taking hypertension medication
(angiotensin-converting-enzyme inhibitor) for more than
20 years. She had never smoked cigarettes and denied
chemical exposure, herb use, or groundwater use. Contrast-
enhanced abdominal computed tomography (CT) showed
sigmoid colon cancer with peritoneal carcinomatosis and
para-aortic lymph node metastasis. Imaging of her urinary
tract revealed bilateral renal pelvis, bilateral ureter, and
bladder urothelial carcinoma.
Because of our patient’s advanced age and acceptable
renal function, aggressive surgical treatment was not a
first priority for the treatment of her urothelial carcinoma.
After discussing the treatment plan with our patient and
her family, we performed a urinary tract tumor biopsy and
laser ablation. We then performed a robotic-assisted sig-
moid colectomy using the da Vinci (Intuitive Surgical,
Mountain View, CA, USA) system, and the pathologic re-
port indicated a diagnosis of pT3N2M0. Examination of
her urinary tract revealed a high-grade infiltrating urothe-
lial carcinoma of the bladder and ureter. No complications
were observed during the operation. Under a generally
stable condition, our patient was discharged on the fourth
day after her operation.
Analysis of codons 12 and 13 of the KRAS gene in the
excised colorectal cancer tissues revealed that they were
mutation-negative (wild type) (Additional file 1 to 3 : Figure S1
to S3 and Additional file 4). Therefore, nine cycles of adjuvant
chemotherapy was initiated with cetuximab (Erbitux; Bristol-
Myers Squibb, Princeton, NJ, USA) and fluorouracil, leucov-
orin, and irinotecan (FOLFIRI) for the treatment of the meta-
static colorectal cancer. As for the urothelial carcinoma of the
bladder, intravesical mitomycin C therapy was administered
five times. Our patient tolerated the chemotherapy well. Cyst-
oscopy, ureterorenoscopy, and urine cytology examinations
were performed every 3 months. The size of the bladder tumor
became smaller (Fig. 1). Surprisingly, a repeat contrast-
enhanced abdominal CT showed shrinkage of the renal pelvis
tumor (Fig. 2), and her hematuria also improved.
Further analysis of the urothelial carcinoma of the
urinary tract was carried out, and the results showed a
wild-type KRAS gene in the urothelial carcinoma tissues.
As of 20 months after the operation, our patient has a
good stable condition without progression of either her
colorectal cancer or urothelial cancer.
Discussion
Currently, there is no standard salvage regimen after
the failure of cisplatin-based chemotherapy for advanced
urothelial carcinoma. Many novel agents have been devel-
oped and have shown modest activity in urothelial carcin-
oma. With the advancement of molecular biology and a
deeper understanding of the pathogenesis of urothelial
carcinoma, new approaches for treating patients using
molecularly targeted therapies have emerged. Previous
studies have shown that the over-expression of epidermal
growth factor receptor (EGFR) predicts poor survival and
stage progression [4, 5]. EGFR is more strongly expressed
in invasive tumors (pT2–T4) and high-grade tumors than
in superficial or low-grade tumors [4]. However, muta-
tions within the kinase domain and truncations of the
EGFR are rarely seen in bladder cancer, and they have
emerged as attractive therapeutic targets. Cetuximab (an
EGFR inhibitor) is a chimeric human/mouse monoclonal
antibody that prevents dimerization by binding to the
extracellular domain of EGFR. Wong et al. [6] conducted
a phase II clinical trial to evaluate the efficacy of cetuxi-
mab with or without paclitaxel as salvage chemotherapy
in patients with previously treated advanced urothelial
cancer. The study was closed after 8 weeks, because 9 of
11 patients had disease progression in the paclitaxel-alone
arm. Progression-free survival greater than 16 weeks was
noted in 12 of 28 patients in the combination arm. They
concluded that cetuximab may augment the activity of
paclitaxel, and the combination merits further study as
salvage chemotherapy in patients with previously treated
urothelial carcinoma. Although the mechanisms are un-
clear, it seems that cetuximab is not effective for use as
a single-agent therapy. Another phase II clinical trial
Fig. 1 Cystoscopy (a–c) shows that the bladder tumor had shrunk. The three pictures were taken over the course of the treatment
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(clinicaltrials.gov ID: NCT00645593) is investigating this
augmentation by evaluating the effect of gemcitabine and
cisplatin chemotherapy either in combination with cetuxi-
mab or not in patients with locally advanced or metastatic
urothelial cancer (above stage T4b), and results are pend-
ing. To date, there have been at least eight clinical trials




Despite the widespread implementation of traditional
cisplatin-based chemotherapy, other clinical trials have in-
cluded synchronous chemotherapy using fluorouracil and
mitomycin C combined with radiotherapy. These trials
demonstrated significant improvements in the control of
bladder cancer compared with radiotherapy alone [7].
Gemcitabine-based and carboplatin-based regimens have
also been studied; Sio et al. [8] demonstrated a 61 % re-
sponse rate with the combination of gemcitabine and
irinotecan.
The Cancer Genome Atlas project performed an inte-
grated analysis of 131 urothelial carcinoma cases to pro-
vide a comprehensive landscape of molecular alterations
[9]. They determined that 69 % of the tumors could poten-
tially be treated, through the use of therapy targeted to the
phosphatidylinositol-3-OH kinase/AKT/mTOR pathway
in 42 % of the tumors or targeted to the RTK/MAPK path-
way (including ERBB2) in 45 % of the tumors. They also
found that urothelial carcinoma had more frequent muta-
tions in chromatin regulatory genes. The current findings
all suggest the future possibility of targeted therapy. The
development of reliable molecular markers is expected to
make personalized treatment strategies possible for the
treatment of urothelial carcinoma. In our case, the un-
expected treatment effect of cetuximab and FOLFIRI in
urothelial carcinoma has not previously been reported.
The urothelial carcinoma in this case harbored the
wild-type form of KRAS, indicating its susceptibility to
cetuximab.
Conclusions
The use of EGFR inhibitors combined with chemother-
apy for the treatment of UTUC may merit further inves-
tigation or evaluation in clinical trials.
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Fig. 2 Repeated contrast-enhanced computed tomography (a–c) shows that the left pelvic tumor, which showed no mutation (wild type), had
shrunk (white arrow). The three pictures were taken over the course of the treatment
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